<DOC>
	<DOCNO>NCT02823574</DOCNO>
	<brief_summary>A study patient metastatic recurrent squamous cell cancer head neck evaluate effectiveness Nivolumab plus Ipilumumab vs. Nivolumab alone ( CheckMate 714 )</brief_summary>
	<brief_title>Study Nivolumab Combination With Ipilimumab Versus Nivolumab Combination With Ipilimumab Placebo Patients With Recurrent Metastatic Squamous Cell Carcinoma Head Neck</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Nivolumab</mesh_term>
	<criteria>For information regard BristolMyers Squibb Clinical Trial participation , please visit www.BMSStudyConnect.com Confirmed squamous cell head neck cancer Widespread ( metastatic ) disease , return previous treatment ( recurrent ) Tumor sample must available analysis PDL1 ( Programmed deathligand 1 ) HPV [ Human Papilloma Virus ( oropharynx ) ] Performance status ECOG 01 ( Eastern Cooperative Oncology Group ) Previous treatment metastatic recurrent disease Cancer arise one follow primary site : paranasal sinus , nasopharynx , salivary gland , skin Any nonsquamous subtype Active autoimmune disease Positive test hepatitis B , C HIV ( Human Immunodeficiency Virus ) virus Previous treatment checkpoint inhibitor drug Active CNS metastases carcinomatous meningitis Other protocol define inclusion/exclusion criterion could apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>